# Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

> **NCT02820961** · PHASE1 · COMPLETED · sponsor: **Syndax Pharmaceuticals** · enrollment: 61 (actual)

## Conditions studied

- Breast Cancer
- Estrogen Receptor Positive Breast Cancer

## Interventions

- **DRUG:** entinostat
- **DRUG:** exemestane

## Key facts

- **NCT ID:** NCT02820961
- **Lead sponsor:** Syndax Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-29
- **Primary completion:** 2018-09-10
- **Final completion:** 2021-07-12
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2021-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02820961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02820961, "Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT02820961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*